YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Earnings Call Insights: Aytu BioPharma (AYTU) Q4 fiscal 2026 MANAGEMENT VIEW * “We finished fiscal 2026 with an encouraging fourth quarter as EXXUA continued to build, our ADHD business performed better than anticipated, and Aytu returned…
Aytu BioPharma, Inc. (AYTU) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.26 per share a year ago. These figures are adjusted for non-recurring items…
* Aytu BioPharma (AYTU [https://seekingalpha.com/symbol/AYTU]) is scheduled to announce Q4 earnings results on Monday, September 21st, after market close. * The consensus EPS Estimate is -$0.35 [https://seekingalpha.com/symbol/AYTU/earning…
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: ACRES Commercial Realty Corp. ACR is a real estate investment trust. The Zacks Consensus Estimate for its current year earnings has been revised 9.8% downward over…
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Aytu BioPharma, Inc. AYTU is a pharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 5.8% downward over the last 60 da…
Image source: The Motley Fool. Date May 13, 2026 Call participants Chief Executive Officer — Joshua R. Disbrow Chief Financial Officer — Ryan J. Selhorn Need a quote from a Motley Fool analyst? Email pr@fool.com Full Conference Call Transc…
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to report quarterly earnings at $0.01 per share on revenue of $72.97 million. • Dominari Holdings (NASDAQ:DOMH) is projected to report earnings for its first quarter…
Aytu BioPharma Inc. (AYTU) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items.…
Image source: The Motley Fool. DATE Tuesday, Feb. 3, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Josh DisbrowChief Financial Officer — Ryan Selhorn Need a quote from a Motley Fool analyst? Email pr@fool.com TAKEAWAYS N…
(RTTNews) - Several small-cap biotech and pharma names posted notable gains in Tuesday's after-hours trading session, with Nutex Health standing out as the most significant mover following its quarterly results. Nutex Health Inc. (NUTX) su…
This article first appeared on GuruFocus. Release Date: November 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Aytu BioPharma Inc (NASDAQ:AYTU) reported net re…
(RTTNews) - Several companies posted notable moves in after-hours trading on Thursday, driven by earnings announcements and regulatory updates. Shares of Milestone Scientific Inc. (MLSS) rose sharply in extended trading, climbing to $0.52,…
Earnings Call Insights: Aytu BioPharma (AYTU) Q1 2026 MANAGEMENT VIEW * CEO Joshua Disbrow highlighted a "very positive and highly productive first quarter," with net revenue for the quarter at $13.9 million. Disbrow emphasized the strong…
Aytu BioPharma Inc. (AYTU) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.2 per share a year ago. These figures are adjusted for non-recurring items.…
Major earnings expected after the bell on Thursday include: * Applied Materials (AMAT [https://seekingalpha.com/symbol/AMAT]) * Virgin Galactic Holdings (SPCE [https://seekingalpha.com/symbol/SPCE]) * Nu Holdings Ltd. (NU [https://seekinga…
* Aytu BioPharma (AYTU [https://seekingalpha.com/symbol/AYTU]) is scheduled to announce Q1 earnings results on Thursday, November 13th, after market close. * The consensus EPS Estimate is -$0.20 [https://seekingalpha.com/symbol/AYTU/earnin…
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Aytu BioPharma AYTU is a healthcare company which focused on commercialization of novel products in the field of urology. The Zacks Consensus Estimate for its curre…
Earnings Call Insights: Aytu BioPharma (AYTU) Q4 2025 MANAGEMENT VIEW * CEO Joshua Disbrow highlighted "the strong financial performance during the recent fiscal year and perhaps more importantly, the upcoming launch of EXXUA, which we bel…
* Aytu BioPharma press release [https://seekingalpha.com/pr/20242010-aytu-biopharma-reports-fiscal-2025-full-year-and-fourth-quarter-operational-and-financial] (NASDAQ:AYTU [https://seekingalpha.com/symbol/AYTU]): Q4 GAAP EPS of -$2.93 mis…
Major earnings expected after the bell on Tuesday include: * Aytu BioPharma (AYTU [https://seekingalpha.com/symbol/AYTU]) * AAR Corp. (AIR [https://seekingalpha.com/symbol/AIR]) * MillerKnoll (MLKN [https://seekingalpha.com/symbol/MLKN]) *…
(RTTNews) - Several biotech names posted strong gains in Monday's after-hours session, driven by clinical updates, strategic shifts, and upcoming catalysts. Volume spikes and late-day news helped push prices higher, setting the stage for p…
* Aytu BioPharma (NASDAQ:AYTU [https://seekingalpha.com/symbol/AYTU]) is scheduled to announce FQ4 earnings results on Tuesday, September 23rd, after market close. * The consensus EPS Estimate is -$0.06 [https://seekingalpha.com/symbol/AYT…
[US Food and Drug Administration (FDA)] While it is not uncommon for pharmaceutical and biotechnology companies to receive warnings letters from the FDA for various reasons, the issuing of around 100 letters recently could be the clearest…
Agilent Technologies (A) came out with quarterly earnings of $1.37 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.32 per share a year ago. These figures are adjusted for non-recurring it…
Aytu BioPharma, Inc. (NASDAQ:AYTU) is one of the best high-return penny stocks to buy now. On July 1, Lake Street Capital Markets initiated coverage on Aytu Biosciences (NASDAQ:AYTU) with a Buy rating and an $8.00 price target, citing stro…
Aytu BioPharma, Inc. (NASDAQ:AYTU) is among the best growth stocks to invest in for the next 5 years. On Monday, Aytu BioPharma, Inc. (NASDAQ:AYTU) disclosed that it has successfully extended its lending agreement with Eclipse Business Cap…
Investing.com - Lake Street Capital Markets initiated coverage on Aytu Biosciences (NASDAQ:AYTU) with a Buy rating and a price target of $8.00 on Tuesday. According to InvestingPro data, the stock is currently trading at attractive valuati…
Aytu BioPharma has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialise Exxua (gepirone) extended-release tablets, a new antidepressant, to the US market for major depressive disorder (MDD). Exxua, developed by…
Emerging Growth MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024. The Emerging Growth Conference id…
Emerging Growth MIAMI, April 02, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024. The Emerging Growth Conference id…
Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the release of a thematic report that examines small market cap pharmaceutical companies based on revenue growth and valuation. The report: Undervalued Gro…
After the completion of local regulatory approvals, Aytu anticipates exporting to Medomie both of its novel, orally disintegrating, extended-release tablets for the treatment of ADHD ENGLEWOOD, CO and GIVATAYIM, ISRAEL / ACCESSWIRE / July…
Company Expects a Six-Month Review of the Prior Approval Supplement Submission by the U.S. Food & Drug Administration Which, if Approved, Enables the Transfer of Cotempla Production to Contract Manufacturer Upon Completion of Manufacturing…
ENGLEWOOD, CO / ACCESSWIRE / June 14, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced Joshua Disbrow, Aytu's Chief Ex…
Abhinav Jain of Nantahala Capital Management, LLC Joins the Company's Board of Directors Upon Closing Potential for Additional $7 Million in Event of Exercise of Common Warrants in Full Extends Interest Only Period on Avenue Capital Term L…
Abhinav Jain of Nantahala Capital Management, LLC Joins the Company's Board of Directors Upon Closing Potential for Additional $7 Million in Event of Exercise of Common Warrants in Full Extends Interest Only Period on Avenue Capital Term L…